-transparent.png){kind=logo}
High-performance liquid chromatography/mass spectrometry (HPLC/MS) was used to identify and elucidate key structural characteristics of a novel dual cyclooxygenase/lipoxygenase inhibitor, tepoxalin (3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl]-N-hydroxy- N-methylpropanamide), its synthesis-related byproducts in bulk drug substance, and degradation products stemming from probe stability studies. Such information is needed to assist in synthesis optimization and in the preparation of stable formulations for toxicity studies and clinical trials. High-performance liquid chromatography, in conjunction with mass spectrometry (HPLC/MS) and UV photodiode array detection, can often expedite the gathering of preliminary data that contribute to several aspects of the pharmaceutical development process.
D J Burinsky, and
B L Armstrong, and
A R Oyler, and
R Dunphy
April 1994,
Journal of pharmaceutical sciences,
D J Burinsky, and
B L Armstrong, and
A R Oyler, and
R Dunphy
August 1993,
Journal of chromatography,
D J Burinsky, and
B L Armstrong, and
A R Oyler, and
R Dunphy
December 1988,
Environmental science & technology,
D J Burinsky, and
B L Armstrong, and
A R Oyler, and
R Dunphy
January 2005,
Rapid communications in mass spectrometry : RCM,
D J Burinsky, and
B L Armstrong, and
A R Oyler, and
R Dunphy
November 2019,
Journal of pharmaceutical and biomedical analysis,
D J Burinsky, and
B L Armstrong, and
A R Oyler, and
R Dunphy
June 2012,
Journal of chromatography. A,
D J Burinsky, and
B L Armstrong, and
A R Oyler, and
R Dunphy
February 1999,
Talanta,
D J Burinsky, and
B L Armstrong, and
A R Oyler, and
R Dunphy
October 1984,
Science (New York, N.Y.),
D J Burinsky, and
B L Armstrong, and
A R Oyler, and
R Dunphy
March 2001,
Journal of chromatography. A,
D J Burinsky, and
B L Armstrong, and
A R Oyler, and
R Dunphy
January 2005,
Rapid communications in mass spectrometry : RCM,
